Singapore-based Prestige BioPharma has entered into 2 new agreements related to its proposed biosimilar trastuzumab, HD201, which it hopes to sell under the brand name Tuznue.
Singapore-based Prestige BioPharma has entered into 2 new agreements related to its proposed biosimilar trastuzumab, HD201, which it hopes to sell under the brand name Tuznue.
The company announced today that it has entered into an exclusive agreement with Pharmapark LLC to supply and commercialize the biosimilar in Russia. Pharmapark, a privately owned Russian pharmaceutical company, currently markets 5 biosimilars in Russia.
The company’s chief executive officer (CEO), Visily Skrypin, said in a statement that Pharmapark looks forward to the opportunity to bring the new product to the market to provide safe and effective treatment for Russian patients who have HER2-positive cancers.
The deal with Pharmapark comes shortly after Mundipharma announced that it had entered into an exclusive license and supply agreement with Prestige to sell the biosimilar in parts of Europe.
The agreement will allow Mundipharma, a network of independent companies that operates in 120 countries worldwide and distributes a number of biosimilars in the European Union, to sell the biosimilar trastuzumab in countries including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland, and Austria after the product’s expected authorization by the European Commission.
In a statement announcing the deal, Lisa S. Park, PhD, CEO of Prestige, said, “We are very pleased to partner with Mundipharma to commercialize our lead biosimilar in the selected European markets. This partnership is an important milestone for Prestige BioPharma, which will further increase the global availability of our trastuzumab biosimilar so that more patients can benefit from its quality and accessibility.” She added that companies see a potential for future expansion of their partnership.
The newly announced agreements are just the latest in a string of deals concerning the biosimilar for Prestige; in late 2018, Prestige announced that it had entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets. Earlier, Prestige announced a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
The proposed biosimilar is currently under review by the European Medicines Agency, and Prestige has also indicated that it plans to file an application for the biosimilar with the FDA in 2019.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.